Standard Biotools Inc (LAB) valuation
Standard Biotools P/E ratio history
Standard Biotools trades at 2.8 times its earnings over the last twelve months.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Dec 31, 2025 | $1.28 | -$0.20 | n/m |
| Dec 31, 2024 | $1.75 | -$0.52 | n/m |
| Dec 31, 2023 | $2.21 | -$0.94 | n/m |
| Dec 31, 2022 | $1.17 | -$2.43 | n/m |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Standard Biotools valuation against its peers
| Company | Market value | P/E | Price / sales |
|---|---|---|---|
| Standard BiotoolsLAB | $238M | 2.8 | 2.8 |
| Lifecore BiomedicalLFCR | $240M | — | — |
| EvommuneEVMN | $242M | 1.2 | 24.2 |
| Fate TherapeuticsFATE | $242M | — | 37.3 |
| AlectorALEC | $245M | — | 17.7 |
| Fulcrum TherapeuticsFULC | $247M | — | — |
| Lexeo TherapeuticsLXEO | $247M | — | — |
| Abeona TherapeuticsABEO | $248M | — | 9.7 |
| Vanda PharmaceuticalsVNDA | $228M | — | 1.1 |
| Peer median | 1.2 | 17.7 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: LAB financials · LAB returns
No forecast, no recommendation. This page describes Standard Biotools Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.